Prevention of Thromboembolic Complications afterSurgical Treatment for Lower Extremity BoneFractures: Experience in Rivaroxaban Use in ClinicalPractice


Comparative evaluation of rivaroxaban (main group, n=37) and enoxaparin (control group, n=29) safety in thromboprophylaxis at closed lower extremity bone fractures treatment was performed. All patients were operated on at terms from 8 to 12 day after injury using external fixation devices. The volume of intra- and perioperative blood loss in the groups did not differ significantly ( p >0.05). The rate of symptomatic thromboembolic complications, i.e. calf deep vein thrombosis confirmed by clinical data, was significantly lower in patients from the main group (2.7%) as compared to the control group (6.8%; p <0.05). No one case of clinically important pulmonary embolism was diagnosed. The obtained data showed that in comparable with enoxaparin clinical efficacy for prevention of venous thromboembolic complications the use of rivaroxaban ensured the better clinical safety, convenience of intake and completeness of prophylaxis scheme without the change of pharmacological support.

Full Text

Restricted Access

About the authors

O. A Kaplunov

Volgograd State Medical University, Volgograd


S. N Biryukov

Volgograd State Medical University, Volgograd

E. Yu Nekrasov

Volgograd State Medical University, Volgograd


  1. Geerts W.H., Bergqvist D., Pineo G.F., Heit J.A., Samama C.M., Lassen M.R. et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008; 133(6 suppl): 381S-453S.
  2. Heit J.A., Spencer F.A., White R.H. The epidemiology of venous thromboembolism. Journal of thrombosis and thrombolysis. 2016; 41 (1): 3-14.
  3. Ageno W. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. Expert review of cardiovascular therapy. 2009; 7 (6): 569-76.
  4. Aglietti P., Lup D., Cuomo P., Baldini A., De Luca L. Total knee arthroplasty using a pie-crusting technique for valgus deformity. Clin. Orthop. Relat. Res. 2007; 464: 73-7.
  5. Carson J.L., Terrin M.L., Noveck H., Sanders D.W., Chaitman B.R., Rhoads G.G. et al.; FOCUS Investigators. Liberal or restrictive transfusion in high-risk patients after hip surgery. N. Engl. J. Med. 2011; 365 (26): 2453-62.
  6. Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 2008; 358 (26): 2765-75.
  7. Lassen M.R., Borris L.C., Nakov R.L. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N. Engl. J. Med. 2002; 34 (10): 726-30.
  8. Jørgensen P.S., Knudsen J.B., Broeng L., Josephsen L., Bjerregaard P., Hagen K. et al. The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study. Clin. Orthop. Relat. Res. 1992; (278): 95-100.
  9. Granero J., de Rada P.D., Lozano L.M., Martínez J., Herrera A. Rivaroxaban versus standard of care in venous thromboembolism prevention following hip or knee arthroplasty in daily clinical practice (Spanish data from the international study XAMOS). Rev. Esp. Cir. Ortop. Traumatol. (English Edition). 2016; 60 (1): 44-52.
  10. Turpie A.G., Lassen M.R., Eriksson B.I., Gent M., Berkowitz, S.D., Misselwitz F. et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty Pooled analysis of four studies. Thromb. Haemost. 2011; 105: 444-53.
  11. Савельев В.С., Чазов Е.И., Гусев Е.И., Кириенко А.И. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология. 2010; 1 (2): 37.
  12. Профилактика венозных тромбоэмболических осложнений в травматологии и ортопедии. Российские клинические рекомендации. Травматология и ортопедия России. 2012; 1 (63): 1-24.
  13. Зырянов С.К., Белоусов Ю.Б. Биоаналоги в современном здравоохранении: что нужно знать клиницисту? Клиническая фармакология и терапия. 2011; 20 (1): 18-20.
  14. Long A., Zhang L., Zhang Y., Jiang B., Mao Z., Li H. et al. Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures. J. Thromb. Thrombolysis. 2014;38 (3): 299-305.



Abstract - 77


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2016 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies